Formulary Decisions
Search for the outcome of decisions made by the Formulary Committee
Guselkumab
Tremfya
Routinely available
SMC (SMC2848)
13/05/2026
Indication
Treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, a biologic treatment, or a Janus kinase (JAK) inhibitor.
Therapeutic Area
Gastro-intestinal system
Status Description
Routinely available in line with national guidance
Formulation
Solution for injection in pre-filled pen and concentrate for solution for infusion
Comments
Link to Advice
Advice Published
10/11/2025
SMC Submission Type
Abbreviated
SMC Status
Accepted